Comparison Study of PF530 and Betaferon in Healthy Subjects

Inclusion Criteria: * Females of childbearing potential must agree to use two effective methods of birth control, practice complete abstinence, or confirm sterilization of monogamous male partner * Males must have had a documented vasectomy, practice complete abstinence or use a condom and refrain from sperm. * Participant is free from clinically significant illness or disease as determined by medical and surgical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory assessments. * Able to understand and sign the written Informed Consent Form Exclusion Criteria: * Female subjects who are pregnant or lactating. * History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, metabolic, psychological, musculoskeletal disease or malignancies unless deemed not clinically significant by the Principal Investigator. * Previous treatment with any interferon product, including investigational use. * Participants with a history of malignant disease, including solid tumours and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured). * Positive screening test for human immunodeficiency virus (HIV). * Positive screening test for hepatitis C antibody (HCV Ab) or current hepatitis B infection (defined as positive for hepatitis surface antigen \[HBsAg\] at Screening). Participants with immunity to hepatitis B (defined as negative HBsAg and positive hepatitis B surface antibody \[HBsAb\]) are eligible to participate in the study. * History of epilepsy, seizure disorder or any unexplained black-outs. * History of hypersensitivity or intolerance to paracetamol or non-steroidal anti-inflammatory drugs (NSAID) that would preclude the use of at least 1 of these during the study. * History of severe allergic or anaphylactic reactions or a known allergy to any component of the interferon β-1b formulation. * History of drug or alcohol abuse less than or equal to 12 months prior to Screening. * History of tobacco use less than or equal to 6 months prior to Screening. * A positive test for drugs of abuse or alcohol during Screening or prior to dosing. * Unwilling or unable to abstain from alcohol from 7 days prior to dosing until end-of-study assessments. * Use of any prescription medication, over-the-counter medication, or herbal supplements/products during Screening or throughout study, unless approved by both the Principal Investigator and the Sponsor.